2019 NOVEL CORONAVIRUS ILLNESS (COVID-19) GUIDANCE

TITLE: Guidance for Healthcare Facilities Concerning 2019 Novel Coronavirus Illness

DATE: March 20, 2020

TIME: 2:00 PM

TO: CURRUS, Inc., Network Pharmacies, and CMHCs

FROM: Commissioner Andrew Brown

SUMMARY: Guidance for Infection Control and Prevention Regarding Patients with Possible Coronavirus Illness; KDADS is providing additional guidance to stakeholders.

GUIDANCE: Temporary Additions to Formulary for Community Support Medication Program

I. Effective immediately the following prescriptions will be added as covered prescriptions under the Community Support Medication Program to ensure that patients who are un-insured or under-insured have immediate access to the following needed medications during the state of emergency;

- **Celexa** between $13 and $24 (4, 3.97, 3.97, 4, 13, 10, 95, 20, 20, 17, 20, 21) average $19.32
- **Lexapro** between $9 and $177 (13, 58, 155, 9, 83, 83, 177, 177, 177) average $103.56
- **Prozac** between $4 and $101 (4, 13, 10, 101, 27, 29, 30, 30, 29) average $30.33
- **Cymbalta** between $19 and $253 (19, 188, 253, 197, 234, 234, 250, 129, 250) average $194.88
- **Wellbutrin** between $21 and $39 (39, 29, 35, 32, 23, 21, 24, 21, 21) average $27.22
- **Prazosin** between $14 and $49 (18, 32, 29, 25, 18, 18, 17, 18, 49, 14, 15) average $22.58
- **Haldol** between $22 and $47 (25, 30, 30, 22, 23, 43, 34, 47, 38, 32, 33) average $32.45
- **Hydroxyzine** between $10.00 and $30.00 average not defined

II. This guidance is effective until the end of the state of emergency, at which time these medications will be reviewed and evaluated to determine if they will remain on the formulary.

III. When possible, prescribers should utilize lower cost alternatives, generics, etc. This effort will help reduce the exhaustion of the Community Support Medication Program funds during the pandemic and still allow for prescriber discretion in treating patients.

IV. Where possible medications should be delivered to patients or provided in a manner that limits the patient and pharmacy staff exposure to transmission.